Pick the Right Patent—or Leave Billions on the Table: The “One Patent Per Product” Rule and the PTE Selection Playbook
In pharma, the difference between winning and losing often isn’t the science. It’s the paperwork—filed in the right order, with the r…

South America’s drug patent landscape is often treated like a black box—until you’re the one trying to launch, defend, or challenge a product.
Here’s the agitation: most teams don’t realize how quickly “country-by-country” becomes “deal-by-deal.” A pat…

Most 505(b)(2) strategies fail before the first filing—because the real competition isn’t the science. It’s the business model.
If you’re a CDMO, specialty lab, or service provider supporting 505(b)(2) follow-on drugs, you already know the pitch: faste…

Combining Lipitor (atorvastatin) with aspirin has been a topic of interest for healthcare professionals due to their common… https://www.Drugchatter.com/chat/18474/what-are-the-effects-of-combining-lipitor-and-aspirin/

Pharma doesn’t just defend patents—it builds a stack.
In a world where “patent cliffs” are treated like weather events, the industry has quietly mastered a more durable strategy: layering exclusivities to make generic entry feel less like a deadline …

India’s “drug patent clock” is not a stopwatch—it’s a moving target. Here’s what actually determines how long exclusivity lasts.
If you work in pharma—whether you’re a brand team, a generic strategist, an investor, or a policy watcher—you’ve probably h…

Generic drugs are in a race—and the rules of the track are changing.
If you’ve ever wondered why some generic launches feel like they happen overnight while others drag on for years, the answer is often buried in a few lines of law: Hatch-Waxman, Par…

Biopharma’s “race to the tender” is really a race to the patent clock.
In Europe, winning drug tenders isn’t just about clinical value, pricing, or supply reliability—it’s about timing your commercial strategy against the legal reality of patent expi…

Biopharma’s next talent migration isn’t happening in the lab—it’s happening in the courtroom.
If you want a real-time read on where biopharma is headed, stop watching press releases and start watching patent litigation dockets.
A new analysis from Drug…

Specialty pharmacy contracts are the new patent cliff. Here’s how biopharma teams can win before the exclusivity window closes.
The patent expiration calendar is familiar to every biopharma operator. But the real commercial inflection point often arriv…